
-   AKR1B10 protein and mRNA expression was increased in early stages of well and moderately differentiated hepatocellular carcinoma samples. In advanced tumor-stages with low grade of differentiation AKR1B10 was downregulated [PMID: 20036025].
-   AKR1B10 mRNA expression was increased in livers of HCC patients exposed to aflatoxin B1 [PMID: 24391771]. Administration of a flavonoid quercetin leads to a dose-dependent increased mRNA expression of Akr1b8 in rat liver [PMID: 19191009]. A higher AKR1B10 mRNA expression level is related to a shorter DFS (disease free survival) and OS (overall survival) in patients with primary hepatocellular carcinoma [PMID: 26948042].
-   Significant increase of AKR1B10 gene and protein expression was observed in steatohepatitis compared to steatosis and normal liver [PMID: 23071592, PMID: 25182422]. Increased AKR1B10 expression in the liver of patients with non-alcoholic fatty liver disease (NASH) compared to those with simple hepatic steatosis and controls, suggesting that AKR1B10 may be a potential biomarker for NASH and progression to HCC [PMID: 30379862, PMID: 25581263]. Gene expression and serum levels of AKR1B10 correlated with disease severity in NASH [PMID: 30870804, PMID: 30707282].
